BioMarin just got good news from the FDA for a treatment of an ultra-rare disorder. But with a price tag of $702,000 a year, is a drug price debate waiting in the wings? Jim Cramer spoke with the CEO for his take.
» Subscribe to CNBC: [ Ссылка ]
» Watch more Mad Money here: [ Ссылка ]
» Read more about BioMarin here: [ Ссылка ]
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: [ Ссылка ]
Watch full episodes: [ Ссылка ]
Follow Mad Money on Twitter: [ Ссылка ]
Like Mad Money on Facebook: [ Ссылка ]
Follow Cramer on Twitter: [ Ссылка ]
Connect with CNBC News Online!
Visit CNBC.com: [ Ссылка ]
Find CNBC News on Facebook: [ Ссылка ]
Follow CNBC News on Twitter: [ Ссылка ]
Follow CNBC News on Google+: [ Ссылка ]
Follow CNBC News on Instagram: [ Ссылка ]
BioMarin CEO: Rare Treatments, High Costs | Mad Money | CNBC
